OMEROS CORP Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Current
OMEROS CORP (OMER) had Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Current of $7.63 million as of 2025-06-30, per its 10-Q filed 2025-08-14.
Financial Statements › Notes › Other Liabilities and Financial Instruments Subject to Mandatory Redemption
us-gaap:SharesSubjectToMandatoryRedemptionSettlementTermsAmountCurrent · last filed 2025-08-14
- 2025-06-30: Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Current $7.63M.
- 2024-12-31: Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Current $0.00.
| Period end | Financial Instruments Subject to Mandatory Redemption, Settlement Terms, Share Value, Amount, Current |
|---|---|
| 2025-06-30 | $7.63M 10-Q · filed 2025-08-14 |
| 2024-12-31 | $0.00 10-Q · filed 2025-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |